Financial Performance - As of March 31, 2025, the company reported a net income of $4,017,775, which included $3,977,942 of interest on the Trust Account[113]. - The company had a cash balance of $1 and a working capital deficit of $10,259,448 as of March 31, 2025[114]. - The company generated non-operating income from interest on marketable securities but has not engaged in any operations or generated revenues to date[112]. Public Offering - The company completed its Public Offering on November 13, 2023, raising gross proceeds of $345.0 million from the sale of 34,500,000 units at $10.00 per unit, incurring transaction costs of approximately $20.4 million[106]. - The underwriters received an underwriting discount of $6,900,000 and deferred underwriting commissions of approximately $12,075,000, contingent upon the completion of a business combination[119][120]. - Offering costs allocated to Class A ordinary shares were charged to temporary equity, while those allocated to Warrants were charged to shareholders' equity[124]. Business Viability - The company has until November 13, 2025, to complete a business combination or cease operations, raising substantial doubt about its ability to continue as a going concern if a business combination is not consummated[117]. Administrative Expenses - The company incurred $30,000 in administrative fees for both the three months ended March 31, 2025, and 2024, under an agreement for office and administrative support[121]. - The company has incurred expenses related to being a public company and due diligence for prospective acquisition candidates[112]. Financing and Capital Structure - The company issued a Working Capital Note for $1,500,000 to Warrant Holdings Sponsor, which is repayable upon consummation of an initial business combination[122]. - The company placed approximately $345.0 million in a Trust Account, invested in U.S. government securities, until the completion of its initial business combination[108]. Compliance and Reporting - The Company complies with ASC 340-10-S99 and SEC Staff Accounting Bulletin Topic 5A regarding offering costs, which primarily consist of professional and registration fees related to the Public Offering[124]. - The Company qualifies as an "emerging growth company" under the JOBS Act, allowing it to delay the adoption of new or revised accounting standards[127]. - As an emerging growth company, the Company is exempt from certain reporting requirements, including auditor's attestation on internal controls and CEO compensation disclosures[128]. - The Company did not have any off-balance sheet arrangements as of the date of the Quarterly Report on Form 10-Q[126]. - The Company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[130].

Exhibit 99.1 As used in this announcement, non-GAAP net income attributable to the Company's shareholders and non-GAAP basic and diluted net income per share and per ADS are defined to exclude share-based compensation expenses. See the unaudited reconciliation of GAAP and non-GAAP results at the end of this announcement. 1 · Net revenues were RMB28.8 billion (US$4.0 billion), an increase of 7.4% compared with the same quarter of 2024. · Games and related value-added services net revenues were RMB24.0 billio ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______, 20___, to _____, 20___. Commission File Number 001-41272 HeartCore Enterprises, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 46-0920988 | | --- | --- | | (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | | 1280 Rancho Conejo Boulevard | | | Thousand Oaks, CA | 91320 | | (Address of Principal Executive Offices) | (Zip Code) | | Registrant's Teleph ...

Exhibit 99.1 Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and commercialization worldwide Atara expects to reduce its operating expenses year-over-year by approximately 65% in 2025 as a result of implemented cost reduction initiatives • Atara has paused development of its CAR T progra ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 84- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-39761 ONDAS HOLDINGS INC. (Exact name of registrant as specified in its charter) incorporation or organization) ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________ FORM 10-Q ____________________________________ (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40034 _________________ ...

____________________________________ FORM 10-Q ____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40034 _________________ ...

Exhibit 99.1 GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI- 0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24) and over two-thirds enrollment completed for the overall trial Cash runway e ...